CareDx, Inc. (CDNA) — Analysis Summary
CareDx, Inc. (CDNA) has a market cap of $2.71B with year-over-year revenue growth of +13.8%. Net margin stands at -5.6%. The stock trades at a P/E ratio of 24.4.
Key Takeaways
- Revenue changed +13.8% year-over-year
- Net margin of -5.6%
- P/E ratio of 24.4
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, CDNA posted revenue growth of +13.8% and trades at a P/E of 24.4.
CareDx, Inc. (CDNA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (23.6%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
765
Headquarters
BRISBANE, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.